Physician profile
Alok Sharma
NPI 1750542049
$21,404.62
in general payments reported to CMS, 2019-2025
11 companies · $636 in 2025
The $636 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,387 · 2020: $1,474 · 2021: $6,626 · 2022: $1,050 · 2023: $485 · 2024: $1,747 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996 · Travel and Lodging: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.32 |
| Travel and Lodging | $871.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $6,287.67 | 2020-2022 | |
| Boston Scientific Corporation | $6,201.71 | 2019-2025 | Crossboss, Avvigo Guidance System, General - Stents |
| Edwards Lifesciences Corporation | $3,045.99 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic Vascular, INC. | $2,852.71 | 2019 | |
| Abbott Laboratories | $1,760.19 | 2019-2025 | Dragonfly Opstar, Coroflow, Amplatzer Amulet |
| Abiomed | $345.82 | 2023-2024 | Impella |
| Medtronic, INC. | $342.29 | 2022-2025 | Corevalve Evolut R, Symplicity G3 |
| Gentuity, LLC | $265.23 | 2024-2025 | Gentuity Hf-Oct Imaging System, Vis-Rx Prime, Vis-Rx |
| Biotronik INC. | $145.36 | 2021 | |
| Teleflex LLC | $121.86 | 2023 | Guideliner |
| Regeneron Healthcare Solutions, INC. | $35.79 | 2025 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.